{"transactions":[{"id":1406803,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":87517,"kind":"organization","name":"Denali Capital Global Investments LLC","position":1,"cik":"0001920832","reported_name":"Denali Capital Global Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2024-09-16T10:05:57.000Z","date":"2024-08-30","kind":"sale","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. (\"Semnur\"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company (\"Scilex\") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the \"SIPA\"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the \"Cash Consideration\") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the \"Scilex Shares\"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. (\"Semnur\"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company (\"Scilex\") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the \"SIPA\"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the \"Cash Consideration\") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the \"Scilex Shares\"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."}],"balance_after":1432500,"derivative":{"underlying":"Class B Ordinary Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-24-078775","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920832/000121390024078775/ownership.xml","form_type":"4"}},{"id":2258633,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":87517,"kind":"organization","name":"Denali Capital Global Investments LLC","position":1,"cik":"0001920832","reported_name":"Denali Capital Global Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-05-24T16:18:58.000Z","date":"2022-05-21","kind":"disposition_to_issuer","acquired":false,"shares":93750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by the Reporting Person, depending on the extent to which the underwriters' over-allotment option is exercised.  The underwriters only partially exercised their over-allotment option, resulting in the Reporting Person forfeiting 93,750 Class B ordinary shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by the Reporting Person, depending on the extent to which the underwriters' over-allotment option is exercised.  The underwriters only partially exercised their over-allotment option, resulting in the Reporting Person forfeiting 93,750 Class B ordinary shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."}],"balance_after":1932500,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001567619-22-011621","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920832/000156761922011621/doc1.xml","form_type":"4"}},{"id":2297888,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":87517,"kind":"organization","name":"Denali Capital Global Investments LLC","position":1,"cik":"0001920832","reported_name":"Denali Capital Global Investments LLC","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2022-04-13T16:54:50.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":510000,"price":10,"value":5100000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Class A Ordinary Shares underlying units (each unit having a price of $10.00 and consisting of one Class A Ordinary Share and one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A Ordinary Share at a price of $11.50 per share) that were acquired by the Reporting Person in a private placement effected concurrently with the closing of the Issuer's initial public offering, based on the partial exercise of the underwriters' over-allotment option."}],"balance_after":510000,"source":{"system":"sec-edgar","filing":"0001140361-22-014407","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920832/000114036122014407/form4.xml","form_type":"4"}}]}